{"id":"NCT02930837","sponsor":"Boehringer Ingelheim","briefTitle":"Safety and Efficacy of Alteplase When Administered in Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4.5 Hours After Stroke Onset","officialTitle":"An Open Label, Multicenter, Single-arm Trial to Assess Safety and Efficacy of Alteplase (Rt-PA) in Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4.5 Hours After Stroke Onset","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-11-15","primaryCompletion":"2017-12-11","completion":"2017-12-11","firstPosted":"2016-10-12","resultsPosted":"2019-08-05","lastUpdate":"2019-08-05"},"enrollment":120,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Stroke"],"interventions":[{"type":"DRUG","name":"alteplase","otherNames":[]}],"arms":[{"label":"alteplase","type":"EXPERIMENTAL"}],"summary":"To evaluate the safety and efficacy of alteplase when administered between 3 and 4.5 hours after onset of stroke symptoms in Chinese patients with acute ischemic stroke","primaryOutcome":{"measure":"The Percentage of Patients With Modified Rankin Scale (mRS 0-1) (Favourable Outcome) Response at Day 90 After Stroke Onset by Face-to-face Interview With Patient","timeFrame":"90 days","effectByArm":[{"arm":"Alteplase (Rt-PA)","deltaMin":42.5,"sd":null}],"pValues":[{"comp":"OG000","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":11,"countries":["China"]},"refs":{"pmids":["32467323"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":120},"commonTop":["Constipation","Hypokalaemia","Hyperhomocysteinaemia","Lung infection","Pneumonia"]}}